NHS Trial Reveals Focal Therapy Halves Prostate Cancer Side Effects for Thousands of Men

A recent National Health Service (NHS) trial, conducted over ten years, has indicated that focal therapy for prostate cancer drastically cuts the risk of debilitating side effects. The study, which monitored nearly 3,500 men across 13 UK hospitals, found that focal therapy led to a 50% reduction in instances of impotence and urinary incontinence when compared to established treatments like radical surgery or radiotherapy.

Focal therapy employs less invasive techniques, such as high-intensity focused ultrasound (HIFU) or cryotherapy, to precisely target and destroy cancerous cells within the prostate while preserving surrounding healthy tissue. This contrasts sharply with traditional methods that often involve removing or irradiating the entire prostate gland, leading to a higher incidence of life-altering complications.

The study found that 90% of men who underwent focal therapy remained free of erectile dysfunction, and 90% retained normal urinary control after five years. In contrast, men treated with radical prostatectomy or radiotherapy commonly report higher rates of these side effects, which can severely impact quality of life.

UCLH consultant urologist Professor Mark Emberton highlighted the significance of these findings, noting that focal therapy could become a preferred option for men with intermediate-risk prostate cancer, providing an effective treatment pathway with a considerably improved side-effect profile. While radical treatments remain vital for aggressive cancers, this research offers a less disruptive alternative for many patients, potentially transforming prostate cancer care within the NHS.